These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1510438)

  • 21. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
    Lister PD; Prevan AM; Sanders CC
    Antimicrob Agents Chemother; 1997 Apr; 41(4):721-7. PubMed ID: 9087477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-spectrum resistance to β-lactams/β-lactamase inhibitors (ESRI) evolved from low-level resistant Escherichia coli.
    Rodríguez-Villodres Á; Gil-Marqués ML; Álvarez-Marín R; Bonnin RA; Pachón-Ibáñez ME; Aguilar-Guisado M; Naas T; Aznar J; Pachón J; Lepe JA; Smani Y
    J Antimicrob Chemother; 2020 Jan; 75(1):77-85. PubMed ID: 31613964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock.
    Joukhadar C; Frossard M; Mayer BX; Brunner M; Klein N; Siostrzonek P; Eichler HG; Müller M
    Crit Care Med; 2001 Feb; 29(2):385-91. PubMed ID: 11246321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Seo YB; Lee J; Kim YK; Lee SS; Lee JA; Kim HY; Uh Y; Kim HS; Song W
    BMC Infect Dis; 2017 Jun; 17(1):404. PubMed ID: 28592240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
    Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
    Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
    Vanjak D; Muller-Serieys C; Picard B; Bergogne-Berezin E; Lambert-Zechovsky N
    Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolution of beta-lactamase inhibitors.
    Livermore DM
    Intensive Care Med; 1994 Jul; 20 Suppl 3():S10-3. PubMed ID: 7962983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of pharmacodynamic parameters of five beta-lactam antibiotics with therapeutic efficacies in an animal model.
    Soriano F; García-Corbeira P; Ponte C; Fernández-Roblas R; Gadea I
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2686-90. PubMed ID: 9124823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. beta-Lactamase-mediated inactivation and efficacy of cefazolin and cefmetazole in Staphylococcus aureus abscesses.
    Fields MT; Herndon BL; Bamberger DM
    Antimicrob Agents Chemother; 1993 Feb; 37(2):203-6. PubMed ID: 8452349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
    Kuo HY; Wang FD; Yen YF; Lin ML; Liu CY
    New Microbiol; 2009 Jan; 32(1):49-55. PubMed ID: 19382669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical on-site monitoring of ß-lactam antibiotics for a personalized antibiotherapy.
    Bruch R; Chatelle C; Kling A; Rebmann B; Wirth S; Schumann S; Weber W; Dincer C; Urban G
    Sci Rep; 2017 Jun; 7(1):3127. PubMed ID: 28600499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of the bovine antimicrobial peptide indolicidin combined with piperacillin/tazobactam in experimental rat models of polymicrobial peritonitis.
    Ghiselli R; Giacometti A; Cirioni O; Mocchegiani F; Orlando F; Silvestri C; Di Matteo F; Abbruzzetti A; Scalise G; Saba V
    Crit Care Med; 2008 Jan; 36(1):240-5. PubMed ID: 18090372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.
    Van der Auwera P; Duchateau V; Lambert C; Husson M; Kinzig M; Sörgel F
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1860-8. PubMed ID: 8239597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
    Attivi D; Gibaud S
    Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.